Vical Incorporated announced the publication in the May 1, 2009 issue of the Journal of General Virology of data from preclinical studies identifying potential targets for development of a herpes simplex virus type 2 (HSV-2) vaccine. HSV-2 is a sexually transmitted virus which is the leading cause of genital herpes. The vaccine under development will be designed for use in people already infected with HSV-2, with the goal of reducing or eliminating periodic viral flare-ups and the associated viral shedding and transmission.
As of today, there is no herpes simplex vaccine, but it is still possible to manage the intensity and frequency of outbreaks. There is a natural antiviral medication that is available without prescription called Dynamiclear. For more information about this topical solution visit the official website.